Clinical Trial Update: Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating rh-endostatin with concurrent chemoradiotherapy followed by durvalumab maintenance in non-small cell lung cancer is listed b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• rh-endostatin (recombinant human endostatin)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Lung Cancer | Phase 4 | Status: UNKNOWN